|30.21||+0.9000||+3.07%||Vol 780.72K||1Y Perf -20.98%|
|Nov 30th, 2023 16:00 DELAYED|
|- -||0.29 0.96%|
|Target Price||64.33||Analyst Rating||Moderate Buy 1.57|
|Potential %||112.94||Finscreener Ranking||★★★★ 52.48|
|Insiders Trans % 3/6/12 mo.||-/-/-88||Value Ranking||★★★★+ 57.75|
|Insiders Value % 3/6/12 mo.||-/-/-98||Growth Ranking||★★★+ 54.54|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-98||Income Ranking||— -|
|Price Range Ratio 52W %||30.81||Earnings Rating||Strong Sell|
|Market Cap||1.43B||Earnings Date||8th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.67|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||586.72K|
|Avg. Monthly Volume||1.11M|
|Avg. Quarterly Volume||658.95K|
Celldex Therapeutics Inc. (NASDAQ: CLDX) stock closed at 30.21 per share at the end of the most recent trading day (a 3.07% change compared to the prior day closing price) with a volume of 780.72K shares and market capitalization of 1.43B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 130 people. Celldex Therapeutics Inc. CEO is Anthony S. Marucci.
The one-year performance of Celldex Therapeutics Inc. stock is -20.98%, while year-to-date (YTD) performance is -32.22%. CLDX stock has a five-year performance of 571.33%. Its 52-week range is between 22.11 and 48.4, which gives CLDX stock a 52-week price range ratio of 30.81%
Celldex Therapeutics Inc. currently has a PE ratio of -19.40, a price-to-book (PB) ratio of 5.98, a price-to-sale (PS) ratio of 2 839.28, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -27.92%, a ROC of -26.87% and a ROE of -29.63%. The company’s profit margin is -%, its EBITDA margin is -8 979.20%, and its revenue ttm is $744.00 Thousand , which makes it $0.02 revenue per share.
Of the last four earnings reports from Celldex Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.67 for the next earnings report. Celldex Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Celldex Therapeutics Inc. is Moderate Buy (1.57), with a target price of $64.33, which is +112.94% compared to the current price. The earnings rating for Celldex Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Celldex Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Celldex Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 27.57, ATR14 : 1.70, CCI20 : 105.88, Chaikin Money Flow : -0.22, MACD : 0.90, Money Flow Index : 52.30, ROC : 12.14, RSI : 61.60, STOCH (14,3) : 99.32, STOCH RSI : 1.00, UO : 54.23, Williams %R : -0.68), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Celldex Therapeutics Inc. in the last 12-months were:
Mon, 06 Nov 2023 13:01 GMT Celldex (CLDX) Gets a Buy from Cantor Fitzgerald- TipRanks. All rights reserved.
Fri, 14 Jul 2023 09:40 GMT Analysts Offer Insights on Healthcare Companies: Celldex (CLDX), RegenXBio (RGNX) and Oculis Holding (OCS)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.